Molnupiravir: everything you need to know about the new Covid pill
UK approves ‘game-changer’ medication for at-risk patients to take at home
The UK has become the first country to approve the use of an oral medication that can be taken at home to treat Covid-19.
Molnupiravir was given the green light today by the UK’s regulatory body for medicines. The pill “will be a game-changer for the most vulnerable and the immunosuppressed”, said Health Secretary Sajid Javid.
Who will get it?
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
The oral antiviral, developed by two US companies – Ridgeback Biotherapeutics and Merck, Sharp & Dohme – has been approved for use by patients with mild to moderate cases of Covid who also present at least one risk factor. Elderly people, diabetics and people with heart disease will be among the first to be offered the treatment.
How does it work?
Molnupiravir works by targeting the enzyme that is responsible for causing the coronavirus to replicate within the body by “introducing errors into its genetic code”, said the BBC. “That should prevent it from multiplying, so keeping virus levels low in the body and reducing the severity of the disease.” Patients can self-administer the medication twice a day, and it is best taken within the first five days of symptoms presenting.
How effective is it?
Clinical trial data showed that the pill “cut the risk of hospitalisation or death by about half” for people at increased risk of developing severe cases of Covid, said the BBC. The Medicines and Healthcare products Regulatory Agency (MHRA) has deemed the treatment both “safe and effective”, with chief executive June Raine describing the medicine as “another therapeutic to add to our armoury against Covid-19”, Sky News reported.
How much does it cost?
The UK has already ordered 480,000 courses of molnupiravir to arrive by the end of the year. Reuters reported that an order for roughly half that amount has also been placed for a similar drug being developed by Pfizer.
The government “has not disclosed” how much the initial Merck, Sharp and Dohme contract has cost, but US authorities struck a deal that worked out at around $700 (£513) per patient, the BBC said. Australia, Singapore and South Korea have also placed orders for the drug.
How long will it take to roll out?
The health secretary said the government is “working at pace” with the NHS to lay out plans to “deploy” the drug to patients “as soon as possible”. He added that it is still “vital” everyone receives a “life-saving Covid-19 vaccine”, as molnupiravir is not a substitute for vaccination.
Penny Ward, a professor in pharmaceutical medicine at King's College London, told the BBC that if trial results are replicated in the UK, “the number of cases requiring hospital admission could be halved and the number of deaths greatly reduced”.
Create an account with the same email registered to your subscription to unlock access.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
Italian senate passes law allowing anti-abortion activists into clinics
Under The Radar Giorgia Meloni scores a political 'victory' but will it make much difference in practice?
By Chas Newkey-Burden, The Week UK Published
-
Magazine interactive crossword - May 3, 2024
Puzzles and Quizzes Issue - May 3, 2024
By The Week US Published
-
Magazine solutions - May 3, 2024
Puzzles and Quizzes Issue - May 3, 2024
By The Week US Published
-
Pros and cons of universal health care
Pros and Cons A medical system that serves everyone comes with its own costs, and they're not only financial
By Rebecca Messina, The Week UK Published
-
Covid four years on: have we got over the pandemic?
Today's Big Question Brits suffering from both lockdown nostalgia and collective trauma that refuses to go away
By Chas Newkey-Burden, The Week UK Published
-
The hollow classroom
Opinion Remote school let kids down. It will take much more than extra tutoring for kids to recover.
By Mark Gimein Published
-
Martha's Rule: patients given right to urgent second opinion
The Explainer Hospitals in England will launch new scheme that will allow access to a rapid treatment review
By Richard Windsor, The Week UK Published
-
The contaminated blood scandal
The Explainer Widely regarded as the worst treatment disaster in the history of the NHS, the public inquiry is due to publish its report in May
By The Week UK Published
-
Can Britain's dental crisis be fixed?
The Explainer New proposals include more money for dentists working in under-served areas
By Richard Windsor, The Week UK Published
-
Excess screen time is making children only see what is in front of them
Under the radar The future is looking blurry. And very nearsighted.
By Devika Rao, The Week US Published
-
Covid-19: what to know about UK's new Juno and Pirola variants
in depth Rapidly spreading new JN.1 strain is 'yet another reminder that the pandemic is far from over'
By Arion McNicoll, The Week UK Published